Company Encyclopedia
View More
name
Eledon Pharmaceuticals
ELDN.US
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.
1.875 T
ELDN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant

    Nov 18 (Reuters) - Eledon Pharmaceuticals Inc:* ELEDON REPORTS PRELIMINARY DATA FROM FIRST SIX PATIENTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART AS THE CORE IMMUNOSUPPRESSANT FOLLOWING ISLET TRANSPLANTATION IN INVESTIGATOR-INITIATED TRIAL AT UCHICAGO MEDICINE* ELEDON PHARMACEUTICALS INC - TEGOPRUBART WELL TOLERATED, NO SERIOUS INFECTIONS OR REJECTION EVENTS Source text: Further company coverage:

    Reuters·
    US
    ELDN
    -10.32%
    Reuters·
    US
    ELDN
    -10.32%

    Eledon Pharmaceuticals shares are trading higher after the company reported preliminary data from the first six patients with Type 1 Diabetes treated with Tegoprubart as the core immunosuppressant following Islet Transplantation in an investigator-Initiated trial at UChicago Medicine.

    benzinga_article·
    US
    ELDN
    -10.32%
    benzinga_article·
    US
    ELDN
    -10.32%

    Eledon Pharmaceuticals Reports Promising Early Results for Tegoprubart in Islet Transplant Trial for Type 1 Diabetes

    Eledon Pharmaceuticals announced promising preliminary results for tegoprubart, an investigational anti-CD40L antibody, in an islet transplant trial for type 1 diabetes. Conducted at the University of Chicago Medicine’s Transplant Institute, the trial showed all six patients in the preliminary cohort achieved insulin independence. The study is funded by Breakthrough T1D, with further research support committed. Results were presented at the Rachmiel Levine-Arthur Riggs Diabetes Research Symposium in Los Angeles.

    Reuters·
    US
    ELDN
    -10.32%
    Reuters·
    US
    ELDN
    -10.32%

    Eledon Pharmaceuticals: Promising Kidney Transplant Program and Strong Financial Position Support Buy Rating

    LifeSci Capital's Rami Katkhuda maintains a Buy rating on Eledon Pharmaceuticals, citing promising kidney transplant program developments and a strong financial position. The Phase II BESTOW study showed tegoprubart's differentiated safety profile, despite not achieving eGFR superiority. Eledon has $93.4 million in cash and plans a Phase III study in 2026. Noble Financial also reiterated a Buy rating with a $10.00 price target.

    Tip Ranks·
    US
    ELDN
    -10.32%
    Tip Ranks·
    US
    ELDN
    -10.32%

    Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

    Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus

    GlobeNewswire·
    US
    ELDN
    -10.32%
    GlobeNewswire·
    US
    ELDN
    -10.32%